联合应用降脂药物的研究进展  

Dyslipidemia and Advances in Lipid Lowering Drugs

作　　者：钟毅[1] 刘挺榕[1] 刘爱华[1] 郭志刚[1] 

机构地区：[1]南方医科大学附属南方医院心内科,广东广州510515

出　　处：《心血管病学进展》2011年第2期216-219,共4页Advances in Cardiovascular Diseases

摘　　要：冠心病是一种多危险因素所致的慢性疾病,血脂异常是其最重要要危险因素。随着糖尿病和代谢综合征发病率增加,混合性高脂血症患病率也随之增加。大量的循证医学研究证实,调脂治疗防治冠心病,首要目标是降低低密度脂蛋白胆固醇,使其降至目标值。但是,在临床实践当中,单药治疗常常不能使低密度脂蛋白胆固醇达标。目前,单用他汀类药物难以达到指南标准,为增加药物疗效和减少不良反应,需要不同药物的联合运用。Dyslipidemia is coronary heart disease caused by multiple risk factors.Increasingly,evidence indicates that diabetes and metabolic syndrome give rise to mixed dyslipidemia.Evidence-based medicine has confirmed that a reduction to target level of low-density lipoprotein cholesterol constituted one of the primary methods for prevention of cardiovascular disease.Unfortunately,monotherapy for dyslipidemia for low-density lipoprotein is less effective.Accordingly,it is necessary to use combined therapy to treat patients with mixed dyslipidemia in order to increase efficacy and reduce side effects.

关 键 词：降脂药物 联合 

分 类 号：R541.4[医药卫生—心血管疾病]